Intrexon ROE 2012-2018 | XON

Current and historical return on equity (ROE) values for Intrexon (XON) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Intrexon ROE for the three months ending September 30, 2018 was -15.71%.
Intrexon ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $-0.20B $0.56B -33.87%
2018-06-30 $-0.18B $0.57B -30.94%
2018-03-31 $-0.13B $0.63B -22.90%
2017-12-31 $-0.12B $0.55B -21.06%
2017-09-30 $-0.13B $0.55B -23.89%
2017-06-30 $-0.12B $0.57B -21.40%
2017-03-31 $-0.15B $0.55B -25.99%
2016-12-31 $-0.19B $0.57B -30.00%
2016-09-30 $-0.18B $0.61B -26.76%
2016-06-30 $-0.18B $0.63B -26.88%
2016-03-31 $-0.18B $0.68B -27.11%
2015-12-31 $-0.09B $0.71B -13.20%
2015-09-30 $-0.03B $0.73B -5.79%
2015-06-30 $-0.05B $0.49B -9.95%
2015-03-31 $-0.06B $0.65B -12.90%
2014-12-31 $-0.08B $0.41B -20.39%
2014-09-30 $-0.11B $0.38B -27.83%
2014-06-30 $-0.05B $0.39B -12.31%
2014-03-31 $-0.01B $0.43B -3.12%
2013-12-31 $-0.06B $0.38B -23.72%
2013-09-30 $-0.05B $0.39B -32.83%
2013-06-30 $-0.08B $0.21B -161.17%
2013-03-31 $-0.09B $0.00B inf%
2012-12-31 $-0.05B $0.00B -240.00%
Sector Industry Market Cap Revenue
Medical Medical Services $1.103B $0.231B
Intrexon Corporation is a biotechnology company. It provides synthetic biology services. The Company designs and produces modular DNA control systems and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery. Intrexon Corporation is based in Germantown, Maryland.
Stock Name Country Market Cap PE Ratio
ICON (ICLR) Ireland $7.844B 24.58
PRA Health Sciences (PRAH) United States $7.421B 30.29
Charles River Laboratories (CRL) United States $6.793B 23.40
NovoCure (NVCR) Jersey $4.947B 0.00
Premier (PINC) United States $4.872B 16.51
Teladoc (TDOC) United States $4.868B 0.00
HealthEquity (HQY) United States $4.810B 94.02
AMN Healthcare Services Inc (AMN) United States $2.603B 16.88
BioTelemetry (BEAT) United States $2.584B 45.64
Medpace Holdings (MEDP) United States $2.505B 31.00
CareDx (CDNA) United States $1.031B 0.00
Natera (NTRA) United States $1.023B 0.00
Healthways (TVTY) United States $0.861B 10.59
China Cord Blood (CO) China $0.808B 22.17
Apollo Medical Holdings (AMEH) United States $0.698B 0.00
Surgery Partners (SGRY) United States $0.665B 0.00
Civitas Solutions (CIVI) United States $0.643B 10.61
Establishment Labs Holdings (ESTA) $0.527B 0.00
OncoCyte (OCX) United States $0.195B 0.00
Imprimis Pharmaceuticals (HROW) United States $0.143B 0.00
Interpace Diagnostics (IDXG) United States $0.027B 0.00
OpGen (OPGN) United States $0.012B 0.00
Cancer Genetics (CGIX) United States $0.007B 0.00
FORM Holdings (XSPA) United States $0.005B 0.00
Biocept (BIOC) United States $0.002B 0.00